CVS Group plc Block Listing Interim Review and TVR Update (6873F)
July 12 2023 - 2:00AM
UK Regulatory
TIDMCVSG
RNS Number : 6873F
CVS Group plc
12 July 2023
12 July 2023
CVS Group plc
("CVS" or the "Company")
Block Listing Interim Review and TVR Update
CVS, one of the UK's leading providers of integrated veterinary
services, makes the following notification pursuant to Schedule Six
of the AIM Rules for Companies regarding its existing block listing
arrangements. References to securities are to the Company's
ordinary shares of 0.2 pence each ("Ordinary Shares").
Name of the company: CVS Group plc
Name of relevant scheme: 1. CVS Group plc 2017-2020 Sharesave Scheme;
2. CVS Group plc 2018-2021 SAYE Sharesave
Scheme; and
3. CVS Group SAYE Plan 1
4. CVS Long Term Incentive Plan
------------------------------------------------------
Period From: 12 January 2023 To: 11 July 2023
of return:
--------- ------------------------- ------ -------------------
Balance of unallotted 1. 230
securities under scheme(s)
from previous return:
2. 12,864
3. 236,142
4. Nil
------------------------------------------------------
Plus: The amount by 1. Nil
which the block scheme(s) 2. Nil
has been increased 3. Nil
since the date of 4. 120,000
the last return (if
any increase has been
applied for):
------------------------------------------------------
Less: Number of securities 1. 0
issued / allotted
under scheme(s) during
period:
2. 0
3. 43,087
4. 3,704
------------------------------------------------------
Equals: Balance under 1. 230
scheme(s) not yet
issued / allotted
at end of period:
2. 12,864
3. 199,633
4. 116,296
------------------------------------------------------
Number and class of 1. 114,302 Ordinary Shares admitted on
securities originally 11 January 2021 and 1,535 Ordinary Shares
listed and the date admitted on 1 September 2021
of admission: 2. 296,069 Ordinary Shares admitted on
1 September 2021
3. 350,000 Ordinary Shares admitted on
30 December 2021
4. 120,000 Ordinary Shares admitted on
15 May 2023
------------------------------------------------------
[1] The Ordinary Shares reserved under the CVS Group SAYE block
listing will satisfy the exercise of option awards under the
Company's SAYE Plan that commenced in 2018, having been approved by
shareholders in general meeting on 30 November 2017 (as previously
announced on 22 December 2021).
Total Voting Rights
The number of securities that have been issued during the block
listing review period stated above includes 43,087 new Ordinary
Shares issued in connection with the exercise of employee share
options under the CVS Group plc 2019-2023 SAYE Sharesave Scheme and
3,704 new Ordinary Shares issued in connection with the exercise of
employee options under the CVS Long Term Incentive Plan 2017.
Following the issue of these new Ordinary Shares, which rank
pari passu in all respects with the Company's existing Ordinary
Shares, the Company has a total issued share capital of 71,427,191
Ordinary Shares, each carrying one voting right. The Company holds
no Ordinary Shares in treasury so the total number of voting rights
is therefore 71,427,191.
This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest, or a change to their interest, in the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Contacts:
CVS Group plc
via Camarco
Richard Fairman, CEO
Scott Morrison, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418
8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBDGDRRUBDGXB
(END) Dow Jones Newswires
July 12, 2023 02:00 ET (06:00 GMT)
CVS (AQSE:CVSG.GB)
Historical Stock Chart
From Oct 2024 to Oct 2024
CVS (AQSE:CVSG.GB)
Historical Stock Chart
From Oct 2023 to Oct 2024